Medical therapy for advanced gastro-entero-pancreatic and bronchopulmonary neuroendocrine tumors

Abstract

Neuroendocrine tumors (NETs) represent a spectrum of rare neoplasms arising in different organism sites. Depending on the site of onset, they also can be distinguished using lab exams (secreting vs. nonsecreting), clinical symptoms (functioning vs. nonfunctioning), behavioral, morphological characteristics (tumor cells’ architectural growth patterns, mitotic and Ki-67 index, presence of necrosis), and grade of cellular differentiation. The aim of this review is to focus on the main signaling pathways targeted by medical treatments of advanced sporadic gastro-entero-pancreatic (GEP) and bronchopulmonary (BP) neuroendocrine neoplasms. The scientific literature regarding treatment of advanced GEP and BP-NETs has been extensively reviewed using MEDLINE and PubMed databases, selecting principal and more recent research articles, clinical trials, and updated guidelines. Somatostatin analogues represent a valid approach to control symptoms in functioning tumors and to inhibit tumor progression in certain categories on the basis of the typical somatostatin receptor expression observed in NETs. The pathogenesis of NETs has been the subject of increased interest in recent years. Many driver mutations pathway genes have been identified as important factors in the carcinogenesis process and, therefore, as potential targets for new anticancer therapies. Activating mutations have been shown in epidermal growth factor receptor, stem cell factor receptor, platelet-derived growth factor receptor, vascular endothelial growth factor, basic-fibroblastic growth factor, transforming growth factor, insulin-like growth factor-1, and their receptors. Effective M-Tor inhibition pathway modulation has led to the approval of drugs in this field such as everolimus. New drugs and several combination regimens with targeted and newer biological agents are being developed and tested in recently conducted and ongoing trials.

Keywords

Gastrointestinal and bronchopulmonary neuroendocrine tumors / advanced disease / medical treatment / targeted agents

References

[1] Cives M.An update on gastroenteropancreatic neuroendocrine tumours..Oncology (Williston Park)2014;28:749-56, 758

[2] Rindi G,Bosman FT,Klimstra DS,Komminoth P.Nomenclature and classification of neuroendocrine neoplasms of the digestive system..2010;Lyon: IARC Press13-14

[3] Sorbye H,Baudin E,Yao JC.Gastroenteropancreatic high-grade neuroendocrine carcinoma..Cancer2014;120:2814-23

[4] La Rosa S.High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back..Endocr Pathol2014;25:193-8

[5] Capdevila J,Halperin I,Yao JC.Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumours..Cancer Metastasis Rev2011;30:27-34

[6] Capdevila J.A shining light in the darkness for the treatment of pancreatic neuroendocrine tumours..Cancer Discov2011;1:213-21

[7] Hilfenhaus G,Pape UF,Jann H,Hess G,Wiedenmann B,Pavel M.Placental growth factor supports neuroendocrine tumour growth and predicts disease prognosis in patients..Endocr Relat Cancer2013;20:305-19

[8] Vallières E,Crowley J,Postmus PE,Chansky K,Goldstraw P.The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer..J Thorac Oncol2009;4:1049-59

[9] Faggiano A,Ducreux M,Duvillard P,Dromain C,Schlumberger M.Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features..Cancer2007;110:265-74

[10] Travis WD.Advances in neuroendocrine lung tumors..Ann Oncol2010;21 Suppl 7:vii65-71

[11] Rekhtmann N.Neuroendocrine tumors of the lung: an update..Arch Pathol Lab Med2010;134:1628-38

[12] Bertino EM,Colonna JE,Otterson GA.Pulmonary neuroendocrine/carcinoid tumors..Cancer2009;115:4434-41

[13] Valente M,Milione M,Formisano B.Common diagnostic challenges in the histopathologic diagnosis of neuroendocrine lung tumors: a case report..Case Rep Oncol2010;3:202-7 PMCID:PMC2920000

[14] Oberg KE.The management of neuroendocrine tumours: current and future medical therapy options..Clin Oncol (R Coll Radiol)2012;24:282-93

[15] Reubi JC.Peptide receptors as molecular targets for cancer diagnosis and therapy..Endocr Rev2003;24:389-427

[16] Modlin IM,Kidd M.Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours..Aliment Pharmacol Ther2010;31:169-88

[17] Bruns C,Briner U,Weckbecker G.SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile..Eur J Endocrinol2002;146:707-16

[18] Patel YC.Somatostatin and its receptor family..Front Neuroendocrinol1999;20:157-98

[19] Møller LN,Hartmann B.Somatostatin receptors..Biochim Biophys Acta2003;1616:1-84

[20] Ruszniewski P,Charyvialle JA,Cloarec D,Raymond JM,Gouerou H,Genestin E,Rougier P.Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: a prospective study in 39 patients..Gut1996;39:279-83 PMCID:PMC1383312

[21] Yamada Y,Wang K,Bell GI.Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney..Proc Natl Acad Sci U S A1992;89:251-5 PMCID:PMC48214

[22] Yamada Y,Law SF,Kubota A,Seino M,Bell GI.Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylate cyclase..Mol Endocrinol1992;6:2136-42

[23] Ben-Shlomo A,Pichurin O,Liu NA,Melmed S.Constitutive somatostatin receptor activity determines tonic pituitary cell response..Mol Endocrinol2009;23:337-48 PMCID:PMC2725764

[24] Cescato R,Waser B,Rivier JE,Schonbrunn A.Agonist-biased signalling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signalling pathways..Mol Endocrinol2010;24:240-9 PMCID:PMC2802896

[25] Reubi JC,Rink H,Mäcke HR.A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors..Eur J Pharmacol2002;456:45-9

[26] Schonbrunn A.Selective agonism in somatostatin receptor signalling and regulation..Mol Cell Endocrinol2008;286:35-9 PMCID:PMC2435097

[27] Ferone D,Semino C,Saveanu A,Moreau JP,Albertelli M,Barreca A.Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation..Am J Physiol Endocrinol Metab2005;289:E1044-50

[28] Arnold R,Creutzfeldt W,Benning M,Jürgensen R,Schäfer H,Dennler HJ.Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours..Gut1996;38:430-8 PMCID:PMC1383075

[29] De Sà SV,Machado MC,Pereira MA,Siqueira SA,Giannella-Neto D.Somatostatin receptors subtype 5 (SSTR5) mRNA expression is related to histopatological features of cell proliferation in insulinomas..Endocr Relat Cancer2006;13:69-78

[30] Schmid HA,van Vugt HH,Schafer J,Sailer AW,Nuciforo P.Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumours..Neuroendocrinology2012;95:232-47

[31] Reubi JC,Krenning E.Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications..J Steroid Biochem Mol Biol1992;4:27-35

[32] Reubi JC.Peptide receptors as molecular targets for cancer diagnosis and therapy..Endocr Rev2003;24:389-427

[33] Reubi JC.Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting..Eur J Nucl Med Mol Imaging2003;30:781-93

[34] Reubi JC.Somatostatin and other Peptide receptors as tools for tumour diagnosis and treatment..Neuroendocrinology2004;80 Suppl 1:51-6

[35] Reubi JC,Wase B,Hipkin RW.Immunoistochemical localisation of somatostatin receptros SST2A in human tumours..Am J Pathol1998;153:233-45

[36] Papotti M,Volante M,Landolfi S,Schindler M,Bussolati G.Expression of somatostatin receptros type 1-5 in 81 cases og gastrointestinal and pancreatic endocrine tumours. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis..Virchovs Arch2002;440:461-75

[37] Volante M,Allìa E,Baragli A,Papotti M.Somatostatin, cortistatin and their receptors in tumours..Mol Cell Endocrinol2008;286:219-29

[38] Lahlou H,Hortala M,Pyronnet S,Susini C.Molecular signalling of somatostatin receptors..Ann N Y Acad Sci2004;1014:121-31

[39] Reisine T.Molecular biology of somatostatin receptors..Endocr Rev1995;16:427-42

[40] Lamberts SW,Reubi JC.The role of somatostatin and its analogs in the diagnosis and treatment of tumours..Endocr Rev1991;12:450-82

[41] Bousquet C,Buscail L,Susini C.Antiproliferative effect of somatostatin and analogs..Chemotherapy2001;47 Suppl 2:30-9

[42] Butturini G,Missiaglia E,Dalai I,Ferdeghini M,Scarpa A.Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma..Endocr Relat Cancer2006;13:1213-21

[43] Schally AV.Oncological applications of somatostatin analogues..Cancer Res1988;48:6977-85

[44] Weckbecker G,Stolz B.Somatostatin analogs for diagnosis and treatment of cancer..Pharmacol Ther1993;60:245-64

[45] Pollak MN.Mechanisms of antineoplastic action of somatostatin analogs..Proc Soc Exp Biol Med1998;217:143-52

[46] Froidevaux S.Somatostatin analogs and radiopeptides in cancer therapy..Biopolymers2002;66:161-83

[47] Schally AV.Chemotherapy targeted to cancers through tumoural hormone receptors..Trends Endocrinol Metab2004;15:300-10

[48] Pyronnet S,Najib S,Laklai H.Antitumour effects of somatostatin..Mol Cell Endocrinol2008;286:230-7

[49] Rinke A,Schade-Brittinger C,Barth P,Mayer C,Pape UF,Harder J,Gress T.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group..J Clin Oncol2009;27:4656-63

[50] Caplin ME,Ćwikla JB,Raderer M,Cadiot G,Capdevila J,Rindi G,Martinez S,Ruszniewski P.Lanreotide in metastatic enteropancreatic neuroendocrine tumours..N Engl J Med2014;371:224-33

[51] Arnold R,Rinke A,Aminossadati B,Mueller HH.Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours (PROMID): results on long-term survival..ASCO2013;31:Abstr 4030

[52] Schmid HA.Pasireotide (SOM230): development, mechanism of action and potential applications..Mol Cell Endocrinol2008;286:69-74

[53] Wolin EM,Eriksson B,Toumpanakis C,Tomassetti P,Fogelman DR,Poon D,Li J,Mahamat A,Newell-Price J,Öberg K.A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumours (NET) with disease-related symptoms inadequately controlled by somatostatin analogs..J Clin Oncol2013;31:abstr s4031

[54] Kulke MH,Phan A,Law L,Freiman J,Jackson J,Kvols L,Zambrowicz B,Sands A.Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide..Endocr Relat Cancer2014;21:705-14 PMCID:PMC4295770

[55] Pavel M,Caplin M,Seufferlein T,Banks P,Sands A,Fleming D.Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial..J Clin Endocrinol Metab2015;100:1511-9

[56] Aparicio T,Baudin E,De Baere T,Schlumberger M.Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours..Eur J Cancer2001;37:1014-9

[57] Filosso PL,Oliaro A,Donati G.Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide..Eur J Cardiothorac Surg2002;21:913-7

[58] Hay N.The Akt-mTOR tango and its relevance to cancer..Cancer Cell2005;8:179-83

[59] Alonso-Gordoa T,Grande E.GEP-NETs Update: Biotherapy for neuroendocrine tumours..Eur J Endocrinol2015;172:R31-46

[60] Jiao Y,Edil BH,Klimstra DS,Schulick RD,Wolfgang CL,Velculescu VE,Vogelstein B,Hruban RH.DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours..Science2011;331:1199-203 PMCID:PMC3144496

[61] Missiaglia E,Barbi S,Falconi M,Piemonti L,Di Florio A,Pederzoli P,Scarpa A.Pancreatic endocrine tumours: expression profiling evidences a role for AKT-mTOR pathway..J Clin Oncol2010;28:245-55 PMCID:PMC4288616

[62] Humar R,Berns H,Battegay EJ.Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signalling..FASEB J2002;16:771-80

[63] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[64] Yao JC,Baudin E Kvols LK,Ruszniewski P,St Peter J,Lebwohl D,Kulke MH,O'Dorisio TM,Cadiot G,Posey JA.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial..J Clin Oncol2010;28:69-76 PMCID:PMC4295034

[65] Yao JC,Ito T,Wolin EM,Hobday TJ,Capdevila J,Tomassetti P,Hoosen S,Lincy J,Öberg K.Everolimus for advanced pancreatic neuroendocrine tumours..N Engl J Med2011;364:514-23 PMCID:PMC4208619

[66] Pavel ME,Baudin E,Hörsch D,Klimovsky J,Jehl V,Oberg K,Yao JC.Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT- 2): a randomised, placebo-controlled, phase 3 study..Lancet2011;378:2005-12

[67] Fazio N,Grossman A,Klimovsky J,Wolin EM.Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study..Chest2013;143:955-62

[68] Duran I,Singh D,Kocha W,Le L,Nicklee T,Birle D,Arboine D,Aviel-Ronen S,Hedley D.A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas..Br J Cancer2006;95:1148-54 PMCID:PMC2360568

[69] Hafsi S,Candido S,Spandidos DA,McCubrey JA,Libra M.Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review)..Int J Oncol2012;40:639-44

[70] Zhang S.PI(3)king apart PTEN's role in cancer..Clin Cancer Res2010;16:4325-30

[71] Ramaswamy S,Vazquez F,Perera S,Sellers WR.Regulation of G1 progression by the PTEN tumour suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway..Proc Natl Acad Sci U S A1999;96:2110-5 PMCID:PMC26745

[72] Myers MP,Batty IH,Stolarov JP,Wigler MH,Tonks NK.The lipid phosphatase activity of PTEN is critical for its tumour suppressor function..Proc Natl Acad Sci U S A1998;95:13513-8 PMCID:PMC24850

[73] Furnari FB,Cavenee WK.The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells..Cancer Res1998;58:5002-8

[74] Putz U,Doan A,Low LH,Tan SS.The tumour suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells..Sci Signal2012;5:ra70

[75] Tamura M,Takino T.Tumour suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas..Cancer Res1999;59:442-9

[76] Kim JS,Li H,Lane WS,Waldman T.Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells..Mol Cell Biol2011;31:2756-71 PMCID:PMC3133370

[77] Wang L,Axiotis CA.Differential expression of the PTEN tumour suppressor protein in fetal and adult neuroendocrine tissues and tumours: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms..Appl Immunohistochem Mol Morphol2002;10:139-46

[78] Collaud S,Atanassoff A,Komminoth P,Weder W.Lung neuroendocrine tumors: correlation of ubiquitinylation 1 and sumoylation with nucleo-cytosolic partitioning of PTEN..BMC Cancer2015;15:74 PMCID:PMC4350902

[79] Samani AA,LeRoith D.The role of the IGF system in cancer growth and metastasis: overview and recent insights..Endocr Rev2007;28:20-47

[80] Furukawa M,Mateo C,Moody TW,Venzon DJ,Jensen RT.Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases..Clin Cancer Res2005;11:3233-42

[81] Chaves J.IGF system in cancer: from bench to clinic..Anticancer Drugs2011;22:206-12

[82] von Wichert G,Hoeflich A,Dralle H,Wiedenmann B,Adler G.Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells..Cancer Res2000;60:4573-81

[83] Nilsson O,Theodorsson E,Ahlman H.Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?.Int J Cancer1992;51:195-203

[84] Nilsson O,McRae A,Ahlman H.Growth factors and carcinoid tumours..Acta Oncol1993;32:115-24

[85] Wulbrand U,Zöfel P,Arnold R.Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours..Eur J Clin Invest1998;28:1038-49

[86] Höpfner M,Huether A,Scherübl H.The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours..Endocr Relat Cancer2006;13:135-49

[87] Vitale L,Huntsman SA,Frabetti F,Facchin F,Zannotti M,Strippoli P.Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumours..Oncol Rep2006;15:1249-56

[88] Richardson PG,Laubach JP,Chanan-Khan AA.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers..Br J Haematol2011;152:367-79

[89] Gloesenkamp C,Lim AR,Vosburgh E,Ocker M,Höpfner M.Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumours..Int J Oncol2012;40:1659-67

[90] Gilbert JA,Lloyd RV,Muders MH.Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors..Pancreas2013;42:411-21 PMCID:PMC3594087

[91] Froesch ER,Schwander J.Actions of insulin-like growth factors..Ann Rev Physiol1985;47:443-67

[92] Schoenle E,Humbel RE.Insulin-like growth factor I stimulates growth of hypophysectomised rats..Nature1982;296:252-3

[93] Adams SO,Handwerger S.Developmental patterns of insulin-like growth factor-I and -II synthesis and regulation in rat fibroblasts..Nature1983;302:150-3

[94] Shi Y,Frost P,Lichtenstein A.Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade..Mol Cancer Ther2005;4:1533-40

[95] Wan X,Shen N,Helman LJ.Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism..Oncogene2007;26:1932-40

[96] O'Reilly KE,She QB,Mills GB,Lane H,Hicklin DJ,Baselga J.mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt..Cancer Res2006;66:1500-8 PMCID:PMC3193604

[97] Rowinsky EK,Tonra JR,Burtrum D.IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor..Clin Cancer Res2007;13:5549-55s

[98] Anthony LB,Leong S,Safran H,Zojwalla NJ.Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma..J Clin Oncol 2010;28;15s

[99] Naing A,Burger A,Lei X,Hong D,Doyle LA,Rohren E,Chandhasin C.Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer..Clin Cancer Res2011;17:6052-60 PMCID:PMC3176947

[100] Rothenberg ML,Sarantopoulos J,Friberg G,McCafferey I,Puzanov I.AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: a subset analysis from the first-in-human study..Presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, January2009;

[101] Strosberg JR,Ryan DP,Fuchs CS,Regan E,Weber J,Kvols LK.A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors..Endocr Relat Cancer2013;20:383-90 PMCID:PMC4029434

[102] Sartelet H,Devouassoux G.Nawrocki-Raby B, Brichon PY, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-1] and VEGF-R2 [KDR/Flk-1]) in tumor lets and in neuroendocrine cell hyperplasia of the lung..Hum Pathol2004;35:1210-7

[103] Bertino EM,Colonna JE,Otterson GA.Pulmonary neuroendocrine/carcinoid tumors..Cancer2009;115:4434-41

[104] Folkman J.Angiogenesis in cancer, vascular, rheumatoid and other disease..Nat Med1995;1:27-31

[105] Berger DP,Dengler WA,Mertelsmann R.Vascular endothelial growth factor (VEGF) mRNA expression in human tumour models of different histologies..Ann Oncol1995;6:817-25

[106] Lawnicka H,Wyczółkowska J,Kunert-Radek J.Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture..Biochem Biophys Res Commun2000;268:567-71

[107] Kuo CJ,Yu EY,Swearingen RA,von Recum HA,Kamihara J,D'Amato R,Mulligan RC.Comparative evaluation of the antitumour activity of antiangiogenic proteins delivered by gene transfer..Proc Natl Acad Sci U S A2001;98:4605-10 PMCID:PMC31881

[108] Matsumoto T.VEGF receptor signal transduction..Sci STKE2001;2001:re21

[109] Klagsbrun M,Mamluk R.The role of neuropilin in vascular and tumour biology..Adv Exp Med Biol2002;515:33-48

[110] Ferrara N,LeCouter J.The biology of VEGF and its receptors..Nat Med2003;9:669-76

[111] Treiber G,Röcken C,Malfertheiner P.Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma..J Cancer Res Clin Oncol2006;132:699-708

[112] Dimitroulopoulos D,Tsamakidis K,Andriotis E,Fotopoulou A,Bazinis A,Paraskevas E.Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial..World J Gastroenterol2007;13:3164-70 PMCID:PMC4436600

[113] Ho QT.Vascular endothelial growth factor: Biology and therapeutic applications..Int J Biochem Cell Biol2007;39:1349-57 PMCID:PMC2752727

[114] O'Farrell AM,Yuen HA,Louie SG,Wong LM,Lee LB,Smolich BD,Murray LJ,Cherrington JM.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo..Blood2003;101:3597-605

[115] Faivre S,Vera K,Lozahic S,Bello C,Brega N,Armand JP,Raymond E.Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer..J Clin Oncol2006;24:25-35

[116] Kulke MH,Meropol NJ,Ryan DP,Bergsland E,Tye L,Li JZ,Fuchs CS.Activity of sunitinib in patients with advanced neuroendocrine tumours..J Clin Oncol2008;26:3403-10

[117] Raymond E,Raoul JL,Borbath I,Valle J,Smith D,Chen JS,Hammel P,Van Cutsem E,Lu DR,Chao R.Sunitinib malate for the treatment of pancreatic neuroendocrine tumours..N Engl J Med2011;364:501-13

[118] Yao JC,Hoff PM,Charnsangavej C,Hess K,Abbruzzese JL.Targeting vascular endothelial growth factor in advanced carcinoid tumour: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b..J Clin Oncol2008;26:1316-23

[119] Faivre S,Dreyer C.Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumours..Endocrinol Metab Clin North Am2010;39:811-26

[120] Chan JA,Earle CC,Bhargava P,Blaszkowsky L,Meyerhardt JA,Fuchs CS.Prospective Study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors..J Clin Oncol2012;l 30:2963-8

[121] Yao JC,Fogleman D,Jacobs CB,Leary C.Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker..J Clin Oncol2010;28 suppl 15:abstr 4002

[122] Sonpavde G.Pazopanib: a novel multitargeted tyrosine kinase inhibitor..Curr Oncol Rep2007;9:115-9

[123] Ahn HK,Kim KM,Choi SH,Park JO,Kang WK,Park YS.Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours..Br J Cancer2013;109:1414-9 PMCID:PMC3776983

[124] Phan AT,Fogelman DR,Ng CS,Malinowski P,Kulke M.A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)..Proc Am Soc Clin Oncol2010;28:abstr 4001

[125] Phan AT,Chan JA,Malinowski P,Ng CS,Kulke MH.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study..Lancet Oncol2015;16:695-703

[126] Wilhelm SM,Tang L,McNabola A,Chen C,Vincent P,Cao Y,Gawlak S,Rowley B,Adnane L,Auclair D,Gedrich R,Riedl B,Bollag G.BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis..Cancer Res2004;64:7099-109

[127] Wilhelm SM,Adnane L,Carter CA,Thierauch KH.Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumour activity..Int J Cancer2011;129:245-55

[128] Bill R,Zumsteg A,Johansson D,Albrecht I,Christofori G.Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model..Clin Cancer Res2015;21:4856-67

[129] Bago-Horvath Z,Grusch M,Hayden H,Komina O,Haitel A,Berger W.Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/ mTOR pathway..Neuroendocrinology2012;96:228-37

[130] Shah T,Frow R,Dhillon AP.Epidermal growth factor receptor expression and activation in neuroendocrine tumours..J Neuroendocrinol2006;18:355-60

[131] Papouchado B,Rohlinger AL,Erlichman C,Lloyd RV.Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas..Mod Pathol2005;18:1329-35

[132] Srivastava A,Lomakin I.Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumours..Hum Pathol2001;32:1184-9

[133] Nilsson O,Kolby L,Ahlman H.Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours..Int J Cancer1995;60:645-51

[134] Krishnamurthy S.Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids..Am J Surg Pathol1997;21:327-33

[135] Shimizu T,Haruma K,Yoshihara M,Kajiyama G.Growth characteristics of rectal carcinoid tumours..Oncology2000;59:229-37

[136] Hobday TJ, Holen K, Donehower RC, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumours (NET): a phase II consortium (P2C) study. J Clin Oncol 2006; 24:189S. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.4043

[137] Modlin IM,Kidd M.Carcinoid tumor and fibrosis: an association with no explanation..Am J Gastroenterol2004;99:2466-78

[138] Yao JC,Rashid A,Szklaruk J,Xie K,Abbruzzese JL.Clinical and in vitro studies of imatinib in advanced carcinoid tumours..Clin Cancer Res2007;13:234-40

[139] Lankat-Buttgereit B,Barth P,Blöcker S.Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumour cell growth..Digestion2005;71:131-40

[140] Schott M,Lettmann M,Scherbaum WA.Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma..Clin Endocrinol (Oxf)2001;55:271-7